Double-Duty drugs: testing a Two-Pronged attack on lung cancer before and after surgery

NCT ID NCT04832854

Summary

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab), given with or without standard chemotherapy, for people with certain stages of non-small cell lung cancer that could be removed by surgery. The goal was to see if giving these drugs both before surgery (to shrink the tumor) and after surgery (to prevent it from coming back) was safe and effective. The trial enrolled 50 participants but was terminated early.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • Columbia University

    New York, New York, 10032-3725, United States

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, 15006, Spain

  • Corporacio Sanitaria Parc Tauli

    Sabadell, Barcelona, 08208, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28222, Spain

  • ICO L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Kantonsspital Baden

    Baden, 5404, Switzerland

  • Kantonsspital Graubünden Medizin Onkologie

    Chur, 7000, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • NYU Cancer Center

    New York, New York, 10016, United States

  • Peter Maccallum Cancer Institute

    Melbourne, Victoria, 3000, Australia

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • St. Vincent's Hospital

    Gyeonggi-do, 16247, South Korea

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575, Australia

  • University of Southern California

    Los Angeles, California, 90033, United States

  • UniversitätsSpital Zürich

    Zurich, 8091, Switzerland

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035, Spain

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Winthrop Univ Hospital

    Mineola, New York, 11501, United States

Conditions

Explore the condition pages connected to this study.